Results 31 to 40 of about 9,774 (195)

FLOW DIVERTER DEVICE IN THE ACUTE SETTING OF RUPTURED BLISTER LIKE ANEURYSM: A CASE REPORT [PDF]

open access: yesEuromediterranean Biomedical Journal, 2021
Blister-like aneurysms (BLA) are a rare half-dome-shaped aneurysm, with a broad-based appearance, originating more often from a non-branching site of the supraclinoid internal carotid artery (ICA).
Cesare Gaglaiardo
doaj   +1 more source

Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. [PDF]

open access: yes, 1999
BACKGROUND: In patients with refractory unstable angina, the platelet glycoprotein IIb/IIIa-receptor antibody abciximab reduces the incidence of cardiac events before and during coronary angioplasty.
Adgey, J. (Jennifer)   +9 more
core   +2 more sources

Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry

open access: yesBMC Cardiovascular Disorders, 2017
Background Thrombolysis is still used when primary angioplasty is delayed for a long time, but 25%–30% of patients require rescue angioplasty (RA). There are no established recommendations for antithrombotic management in RA.
José M. De la Torre Hernández   +10 more
doaj   +1 more source

Abciximab‐Associated Thrombocytopenia After Previous Tirofiban‐Related Thrombocytopenia [PDF]

open access: yes, 2006
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90080/1/phco.26.3.423 ...
Dorsch, Michael P.   +3 more
core   +1 more source

P2Y12 Receptor Blockade Augments Glycoprotein IIb‐IIIa Antagonist Inhibition of Platelet Activation, Aggregation, and Procoagulant Activity [PDF]

open access: yes, 2014
Background: New antiplatelet agents that provide greater, more consistent inhibition of the platelet ADP receptor P2Y12 may be used in combination with glycoprotein (GP) IIb‐IIIa antagonists, but their combined effect on platelet function and ...
Barnard, Marc R.   +5 more
core   +1 more source

The use of combination of fibrinolytic therapy and abciximab in the treatment of the acute myocardial infarction with ST elevation [PDF]

open access: yesVojnosanitetski Pregled, 2002
Background. According to current knowledge, the best way to treat the acute myocardial infarction with ST elevation is primary transluminal coronary angioplasty, which can be performed only in the best equipped tertiary cardiology centers.
Gligić Branko   +4 more
doaj   +1 more source

Soluble CD40 ligand in acute coronary syndromes [PDF]

open access: yes, 2003
BACKGROUND: CD40 ligand is expressed on platelets and released from them on activation. We investigated the predictive value of soluble CD40 ligand as a marker for clinical outcome and the therapeutic effect of glycoprotein IIb/IIIa receptor inhibition ...
Boersma, H. (Eric)   +6 more
core   +1 more source

Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor Abciximab in Unstable Angina [PDF]

open access: yes, 2003
BACKGROUND: This study was designed to investigate long-term effects of the glycoprotein IIb/IIIa inhibitor abciximab in patients with acute coronary syndrome without ST elevation who were not scheduled for coronary intervention.
Armstrong, P.W. (Paul)   +9 more
core   +3 more sources

Intracoronary abciximab in STEMI using local drug delivery catheter – Single center experience

open access: yesIndian Heart Journal, 2013
Background: Despite restoration of epicardial flow during primary PCI in STEMI, microvascular obstruction may persist as a result of both atheromatous and thrombotic embolization and vasospasm.
G. Sengottuvelu, V. Ravi Sekar
doaj   +1 more source

Morphine Analgesia Pre-PPCI Is Associated with Prothrombotic State, Reduced Spontaneous Reperfusion and Greater Infarct Size [PDF]

open access: yes, 2017
Schattauer GmbH Stuttgart.The emergency management of ST-elevation myocardial infarction (STEMI) involves treatment with dual-antiplatelet therapy (DAPT) and primary percutaneous coronary intervention (PPCI). Pain is generally treated with opiates, which
Farag, Mohamed   +5 more
core   +2 more sources

Home - About - Disclaimer - Privacy